- Home
- XERS vs ISD Comparison
XERS vs ISD Comparison
Compare XERS & ISD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XERS
- ISD
- Stock Information
- Founded
- XERS 2005
- ISD 2012
- Country
- XERS United States
- ISD United States
- Employees
- XERS N/A
- ISD N/A
- Industry
- XERS Biotechnology: Pharmaceutical Preparations
- ISD Trusts Except Educational Religious and Charitable
- Sector
- XERS Health Care
- ISD Finance
- Exchange
- XERS Nasdaq
- ISD Nasdaq
- Market Cap
- XERS 500.2M
- ISD 460.9M
- IPO Year
- XERS 2018
- ISD N/A
- Fundamental
- Price
- XERS $3.47
- ISD $13.93
- Analyst Decision
- XERS Buy
- ISD
- Analyst Count
- XERS 3
- ISD 0
- Target Price
- XERS $4.87
- ISD N/A
- AVG Volume (30 Days)
- XERS 1.8M
- ISD 127.1K
- Earning Date
- XERS 11-08-2024
- ISD 01-01-0001
- Dividend Yield
- XERS N/A
- ISD 9.69%
- EPS Growth
- XERS N/A
- ISD N/A
- EPS
- XERS N/A
- ISD N/A
- Revenue
- XERS $187,361,000.00
- ISD N/A
- Revenue This Year
- XERS $24.27
- ISD N/A
- Revenue Next Year
- XERS $18.57
- ISD N/A
- P/E Ratio
- XERS N/A
- ISD N/A
- Revenue Growth
- XERS 22.72
- ISD N/A
- 52 Week Low
- XERS $1.69
- ISD $10.98
- 52 Week High
- XERS $3.87
- ISD $13.17
- Technical
- Relative Strength Index (RSI)
- XERS 54.75
- ISD 51.49
- Support Level
- XERS $3.32
- ISD $13.35
- Resistance Level
- XERS $3.57
- ISD $14.31
- Average True Range (ATR)
- XERS 0.18
- ISD 0.19
- MACD
- XERS -0.01
- ISD -0.03
- Stochastic Oscillator
- XERS 42.86
- ISD 60.42
About XERS Xeris Biopharma Holdings Inc.
Xeris Biopharma Holdings Inc is a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology. The company has three commercially available products, Gvoke, ready-to-use liquid glucagon for the treatment of severe hypoglycemia, Keveyis, the first FDA-approved therapy for primary periodic paralysis, and Recorlev, approved by the FDA for the treatment of endogenous hypercortisolemia in adult patients with Cushing's Syndrome. The Company also has a pipeline of development programs to bring new products forward using its proprietary formulation science, XeriSol and XeriJect.
About ISD PGIM High Yield Bond Fund Inc.
PGIM High Yield Fund Inc is a diversified, closed-end management investment company, active in the financial services domain. The Fund's investment objective is to provide a high level of current income. It invests at least 80% of its investable assets in a diversified portfolio of high-yield fixed-income instruments that are rated below investment grade with varying maturities and other investments.